Liberum Appointed as Nominated Adviser & Broker

RNS Number : 9076Z

Futura Medical PLC

23 May 2019

 

Futura Medical

Appointment of Liberum as Nominated Adviser and Broker

23 May 2019

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces the appointment, with immediate effect, of Liberum Capital Limited ("Liberum") as its Nominated Adviser and sole Broker.

ENDS

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [e-mail]
Tel: [phone]
 

Nominated Adviser and Broker:
Liberum
Bidhi Bhoma

Euan Brown

Kane Collings
Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [e-mail]

Tel: [phone]

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

END

 

 

APPQLLFLKEFFBBK